論文

査読有り 国際誌
2018年7月

Japanese guideline for the treatment of idiopathic pulmonary fibrosis.

Respiratory investigation
  • Sakae Homma
  • ,
  • Masashi Bando
  • ,
  • Arata Azuma
  • ,
  • Susumu Sakamoto
  • ,
  • Keishi Sugino
  • ,
  • Yoshiki Ishii
  • ,
  • Shinyu Izumi
  • ,
  • Naohiko Inase
  • ,
  • Yoshikazu Inoue
  • ,
  • Masahito Ebina
  • ,
  • Takashi Ogura
  • ,
  • Kazuma Kishi
  • ,
  • Tomoo Kishaba
  • ,
  • Takashi Kido
  • ,
  • Akihiko Gemma
  • ,
  • Yoshihito Goto
  • ,
  • Shinichi Sasaki
  • ,
  • Takeshi Johkoh
  • ,
  • Takafumi Suda
  • ,
  • Kazuhisa Takahashi
  • ,
  • Hiroki Takahashi
  • ,
  • Yoshio Taguchi
  • ,
  • Hiroshi Date
  • ,
  • Hiroyuki Taniguchi
  • ,
  • Takeo Nakayama
  • ,
  • Yasuhiko Nishioka
  • ,
  • Yoshinori Hasegawa
  • ,
  • Noboru Hattori
  • ,
  • Junya Fukuoka
  • ,
  • Atsushi Miyamoto
  • ,
  • Hiroshi Mukae
  • ,
  • Akihito Yokoyama
  • ,
  • Ichiro Yoshino
  • ,
  • Kentaro Watanabe

56
4
開始ページ
268
終了ページ
291
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.resinv.2018.03.003

Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. It has a very poor prognosis with a 5-year survival rate of 30% or below, and so far there has been no guideline in Japan offering an established effective therapy based on evidence. In addition to the establishment of basic therapies, there is also an urgent need to establish therapies to deal with complications, as death occurs in many cases due to acute exacerbation or comorbid lung cancer. It was therefore decided to formulate a guideline in order to promote evidence-based clinical practice, to further improve the quality of medical treatment in the clinical setting, and to allow the benefits to be enjoyed by the public.

リンク情報
DOI
https://doi.org/10.1016/j.resinv.2018.03.003
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29980444

エクスポート
BibTeX RIS